Safety Study of SCIO-469 to Treat Patients With Active Rheumatoid Arthritis Receiving Methotrexate
Rheumatoid Arthritis
About this trial
This is an interventional treatment trial for Rheumatoid Arthritis focused on measuring Rheumatoid arthritis, Scio-469
Eligibility Criteria
Inclusion Criteria: Patients who have active rheumatoid arthritis and are receiving methotrexate meet the revised 1987 American Rheumatism Association (ARA) criteria for rheumatoid arthritis has active RA as demonstrated by 9 tender and 6 swollen joints and one of the following: C-reactive protein 1.0 mg/dL, Erythrocyte sedimentation rate (ESR) 28 mm/hour, or Morning stiffness = 45 minutes. . Exclusion Criteria: Patient used etanercept, infliximab, anakinra, or an experimental biologic agent within past 3 months Had elevation of liver enzymes within past 6 months Has a history of Tuberculosis Vertigo, inner ear, or vestibular abnormalities Cancer HIV-positive Abnormal electrocardiogram patient has chronic or acute infection Multiple sclerosis, neuropathy or encephalopathy